Global Keratoconus Treatment Market

$4,450$6,250

The global IPM pheromone products market is anticipated to exhibit a healthy CAGR of 8.54% to surpass a value of USD 2,850.60 million by the end of 2028.

Clear

Description

Global Keratoconus Treatment Market

Market Overview
According to CRI, the global keratoconus treatment market is expected to exhibit a healthy CAGR of 4.72% during the review period. Keratoconus is a reformist eye condition where the cornea, normally round and little, seems cone-like. Keratoconus often has to do with light overexposure, steady eye scouring, inappropriately fitting contact focal points and persistent eye aggravation. Keratoconus care relies upon the reality of the illness and how effectively the condition advances.
The market growth of the global keratoconus treatment market is driven by the rising incidence and prevalence of keratoconus disorders, Increasing ultraviolet and sun exposure, and supportive government regulations. additionally, increasing healthcare infrastructure in developing countries further provides significant growth opportunities for the market. However, the Side-effects of keratoconus treatment are estimated to restrain the growth of the global market during the review period.

Segment Overview
The Global Keratoconus Treatment Market has been classified into Keratoconus Type, Treatment Type.
Based on Keratoconus Type the global market is classified into Corneal Hydrops, Forme Fruste Keratoconus Posterior Keratoconus, Keratoglobus, Pellucid Marginal Degeneration, and Others.
Depending on Treatment Type the market has been divided into Corneal Cross-Linking, Lenses, Surgery, and others. The lenses segment is further classified into Soft Contact Lenses, Gas Permeable Contact Lenses, Scleral, and Semi-Scleral Lenses Piggybacking Contact Lenses, Hybrid Contact Lenses, Prosthetic Lenses, and Others. The Surgery is subcategorized into Corneal Transplant, Intacs, and Others. The End User segment classifies the global market into Eye Clinics, Hospitals, and Others.
Regional Analysis:
Geographically, the global Keratoconus Treatment market has been studied across the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is set to lead the global market owing to the well-established healthcare industry and medical facilities and accelerating technological innovations in the region. Europe contributed a significant share of the global keratoconus treatment market owing to the rising support from the government, the advanced medical industry in the region, and the increasing cases of keratoconus.
Asia-Pacific is likely to register the fastest-growing regional market owing to the high merger and acquisition activities and product approvals in the region. The keratoconus treatment market in the Middle East and Africa is relied upon to observe consistent development during the survey time frame. In the Middle East, the reception pace of more current analytic instruments was high in South Africa, the UAE, and Saudi Arabia. With the expanding vital drives by private and public firms and associations, the development rate is relied upon to ascend in the following not many years.
Major Players
The major market players of global keratoconus treatment include HOYA Vision Care Company (Japan), Menicon Co., Ltd. (Japan), Cooper Companies, Inc. (US), Bausch Health (Canada), SynergEyes (US), Carl Zeiss Meditec AG (Germany), Contamac (UK), SEED Co., Ltd (Japan), Novartis AG (Switzerland), and Johnson & Johnson Services, Inc. (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

1.1 OVERVIEW 14

2 MARKET INTRODUCTION 15

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

2.3 LIST OF ASSUMPTIONS 16

3 RESEARCH METHODOLOGY 17

3.1 OVERVIEW 17

3.2 DATA MINING 17

3.3 SECONDARY RESEARCH 18

3.4 PRIMARY RESEARCH 19

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 21

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 23

3.7 DATA TRIANGULATION 24

3.8 VALIDATION 24

4 MARKET DYNAMICS 25

4.1 INTRODUCTION 25

4.2 DRIVERS 26

4.2.1 INCREASING INCIDENCE AND PREVALENCE OF THE KERATOCONUS DISORDER 26

4.2.2 INCREASING ULTRAVIOLET AND SUN EXPOSURE 26

4.2.3 FAVORABLE GOVERNMENT FUNDING 27

4.3 RESTRAINTS 28

4.3.1 LACK OF AWARENESS 28

4.3.2 SIDE-EFFECTS OF KERATOCONUS TREATMENT 28

4.4 OPPORTUNITIES 29

4.4.1 EMERGING MARKETS OF KERATOCONUS TREATMENT 29

5 MARKET FACTOR ANALYSIS 30

5.1 VALUE CHAIN ANALYSIS 30

5.1.1 R&D AND DESIGNING 31

5.1.2 MANUFACTURING 31

5.1.3 DISTRIBUTION 31

5.1.4 MARKETING & SALES 31

5.2 PORTER’S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 32

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 33

5.2.4 BARGAINING POWER OF BUYERS 33

5.2.5 INTENSITY OF RIVALRY 33

5.3 COVID-19 IMPACT ANALYSIS 33

5.3.1 IMPACT ON MARKET GROWTH 33

5.3.2 IMPACT ON DEMAND AND SUPPLY 34

5.3.3 IMPACT ON MAJOR PLAYERS 34

6 GLOBAL KERATOCONUS TREATMENT MARKET, BY KERATOCONUS TYPE 35

6.1 OVERVIEW 35

6.2 CORNEAL HYDROPS 36

6.3 FORME FRUSTE KERATOCONUS 36

6.4 POSTERIOR KERATOCONUS 37

6.5 KERATOGLOBUS 37

6.6 PELLUCID MARGINAL DEGENERATION 38

6.7 OTHERS 38

7 GLOBAL KERATOCONUS TREATMENT MARKET, BY TREATMENT TYPE 39

7.1 OVERVIEW 39

7.2 CORNEAL CROSS-LINKING 40

7.3 LENSES 40

7.4 SURGERY 42

7.5 OTHERS 43

8 GLOBAL KERATOCONUS TREATMENT MARKET, BY END USER 44

8.1 OVERVIEW 44

8.2 EYE CLINICS 45

8.3 HOSPITALS 45

8.4 OTHERS 46

9 GLOBAL KERATOCONUS TREATMENT MARKET, BY REGION 47

9.1 OVERVIEW 47

9.2 AMERICA 48

9.2.1 NORTH AMERICA 52

9.2.1.1 US 55

9.2.1.2 CANADA 57

9.2.2 LATIN AMERICA 59

9.3 EUROPE 61

9.3.1 WESTERN EUROPE 64

9.3.1.1 GERMANY 67

9.3.1.2 FRANCE 69

9.3.1.3 UK 71

9.3.1.4 ITALY 73

9.3.1.5 SPAIN 75

9.3.1.6 REST OF WESTERN EUROPE 77

9.3.2 EASTERN EUROPE 79

9.4 ASIA-PACIFIC 81

9.4.1 CHINA 84

9.4.2 INDIA 86

9.4.3 JAPAN 88

9.4.4 SOUTH KOREA 90

9.4.5 AUSTRALIA 92

9.4.6 REST OF ASIA-PACIFIC 94

9.5 MIDDLE EAST & AFRICA 96

9.5.1 MIDDLE EAST 99

9.5.2 AFRICA 101

10 COMPETITIVE LANDSCAPE 103

10.1 OVERVIEW 103

10.2 COMPETITIVE BENCHMARKING 104

10.3 GLOBAL KERATOCONUS TREATMENT MARKET: COMPANY RANKING, 2019 105

10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL KERATOCONUS TREATMENT MARKET 106

10.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 106

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 107

10.6.1 PRODUCT APPROVALS AND LAUNCHES 107

10.6.2 ACQUISITIONS & SPIN OFF 108

10.7 FINANCIAL MATRIX 109

11 COMPANY PROFILES 110

11.1 BAUSCH HEALTH COMPANIES INC. 110

11.1.1 COMPANY OVERVIEW 110

11.1.2 FINANCIAL OVERVIEW 111

11.1.3 PRODUCTS/SERVICES OFFERED 112

11.1.4 KEY DEVELOPMENTS 112

11.1.5 SWOT ANALYSIS 113

11.1.6 KEY STRATEGIES 113

11.2 NOVARTIS AG 114

11.2.1 COMPANY OVERVIEW 114

11.2.2 FINANCIAL OVERVIEW 115

11.2.3 PRODUCTS/SERVICES OFFERED 115

11.2.4 KEY DEVELOPMENTS 116

11.2.5 SWOT ANALYSIS 116

11.2.6 KEY STRATEGIES 116

11.3 THE COOPER COMPANIES, INC. 117

11.3.1 COMPANY OVERVIEW 117

11.3.2 FINANCIAL OVERVIEW 117

11.3.3 PRODUCTS/SERVICES OFFERED 118

11.3.4 KEY DEVELOPMENTS 118

11.3.5 SWOT ANALYSIS 119

11.3.6 KEY STRATEGIES 119

11.4 HOYA CORPORATION 120

11.4.1 COMPANY OVERVIEW 120

11.4.2 FINANCIAL OVERVIEW 120

11.4.3 PRODUCTS/SERVICES OFFERED 121

11.4.4 KEY DEVELOPMENTS 121

11.4.5 SWOT ANALYSIS 122

11.4.6 KEY STRATEGIES 122

11.5 JOHNSON & JOHNSON SERVICES, INC. 123

11.5.1 COMPANY OVERVIEW 123

11.5.2 FINANCIAL OVERVIEW 124

11.5.3 PRODUCTS/SERVICES OFFERED 125

11.5.4 KEY DEVELOPMENTS 126

11.5.5 SWOT ANALYSIS 126

11.5.6 KEY STRATEGIES 126

11.6 CARL ZEISS MEDITEC AG 127

11.6.1 COMPANY OVERVIEW 127

11.6.2 FINANCIAL OVERVIEW 127

11.6.3 RODUCTS/SERVICES OFFERED 128

11.6.4 KEY DEVELOPMENTS 128

11.6.5 SWOT ANALYSIS 129

11.6.6 KEY STRATEGIES 129

11.7 CONTAMAC 130

11.7.1 COMPANY OVERVIEW 130

11.7.2 FINANCIAL OVERVIEW 130

11.7.3 PRODUCTS/SERVICES OFFERED 130

11.7.4 KEY DEVELOPMENTS 131

11.7.5 SWOT ANALYSIS 131

11.7.6 KEY STRATEGIES 131

11.8 SEED CO., LTD 132

11.8.1 COMPANY OVERVIEW 132

11.8.2 FINANCIAL OVERVIEW 132

11.8.3 PRODUCTS/SERVICES OFFERED 133

11.8.4 KEY DEVELOPMENTS 133

11.8.5 SWOT ANALYSIS 134

11.8.6 KEY STRATEGIES 134

11.9 SYNERGEYES 135

11.9.1 COMPANY OVERVIEW 135

11.9.2 FINANCIAL OVERVIEW 135

11.9.3 PRODUCTS/SERVICES OFFERED 135

11.9.4 KEY DEVELOPMENTS 136

11.9.5 SWOT ANALYSIS 136

11.9.6 KEY STRATEGIES 136

11.10 MENICON CO., LTD 137

11.10.1 COMPANY OVERVIEW 137

11.10.2 FINANCIAL OVERVIEW 137

11.10.3 PRODUCTS/SERVICES OFFERED 138

11.10.4 KEY DEVELOPMENTS 139

11.10.5 SWOT ANALYSIS 139

11.10.6 KEY STRATEGIES 139

12 APPENDIX 140

12.1 REFERENCES 140

12.2 RELATED REPORTS 140

RSS
Follow by Email